Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study

BACKGROUND: Selective BCL2 inhibition with venetoclax has substantial activity in patients with relapsed or refractory chronic lymphocytic leukaemia. Combination therapy with rituximab enhanced activity in preclinical models. The aim of this study was to assess the safety, pharmacokinetics, and acti...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Lancet Oncol
Autores principales: Seymour, John F, Ma, Shuo, Brander, Danielle M, Choi, Michael Y, Barrientos, Jacqueline, Davids, Matthew S, Anderson, Mary Ann, Beaven, Anne W, Rosen, Steven T, Tam, Constantine S, Prine, Betty, Agarwal, Suresh K, Munasinghe, Wijith, Zhu, Ming, Lash, L Leanne, Desai, Monali, Cerri, Elisa, Verdugo, Maria, Kim, Su Young, Humerickhouse, Rod A, Gordon, Gary B, Kipps, Thomas J, Roberts, Andrew W
Formato: Artigo
Lenguaje:Inglês
Publicado: 2017
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5316338/
https://ncbi.nlm.nih.gov/pubmed/28089635
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(17)30012-8
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares